# Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine

> **NCT05718037** · PHASE1 · UNKNOWN · sponsor: **Wuhan BravoVax Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Recombinant Zoster Vaccine
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Zoster Vaccine Recombinant, Adjuvanted

## Key facts

- **NCT ID:** NCT05718037
- **Lead sponsor:** Wuhan BravoVax Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-01
- **Primary completion:** 2024-01-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05718037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05718037, "Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05718037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*